tiprankstipranks
Trending News
More News >
Wuxi Biologics (Cayman) Inc. (HK:2269)
:2269
Hong Kong Market

Wuxi Biologics (Cayman) (2269) Ratios

Compare
42 Followers

Wuxi Biologics (Cayman) Ratios

HK:2269's free cash flow for Q4 2024 was ¥0.00. For the 2024 fiscal year, HK:2269's free cash flow was decreased by ¥ and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
1.98 2.78 1.98 2.37 3.16
Quick Ratio
1.74 2.54 1.74 2.16 2.92
Cash Ratio
0.69 1.27 0.69 1.09 1.58
Solvency Ratio
0.39 0.36 0.39 0.34 0.25
Operating Cash Flow Ratio
0.59 0.61 0.59 0.42 0.42
Short-Term Operating Cash Flow Coverage
4.19 8.10 4.19 1.62 2.45
Net Current Asset Value
¥ 5.12B¥ 8.64B¥ 5.12B¥ 8.20B¥ 6.14B
Leverage Ratios
Debt-to-Assets Ratio
0.09 0.08 0.09 0.10 0.12
Debt-to-Equity Ratio
0.13 0.11 0.13 0.13 0.16
Debt-to-Capital Ratio
0.11 0.10 0.11 0.12 0.14
Long-Term Debt-to-Capital Ratio
0.04 0.04 0.04 0.02 0.08
Financial Leverage Ratio
1.41 1.40 1.41 1.36 1.41
Debt Service Coverage Ratio
3.91 6.67 3.91 1.86 2.52
Interest Coverage Ratio
95.67 28.08 95.67 98.42 41.14
Debt to Market Cap
0.01 0.02 0.01 <0.01 <0.01
Interest Debt Per Share
1.08 1.13 1.08 0.98 0.80
Net Debt to EBITDA
-0.32 -0.93 -0.32 -1.04 -1.63
Profitability Margins
Gross Profit Margin
44.04%40.08%44.04%46.93%45.13%
EBIT Margin
35.51%25.43%35.51%39.19%35.79%
EBITDA Margin
40.76%32.30%40.76%43.87%41.19%
Operating Profit Margin
40.34%26.12%40.34%37.48%31.33%
Pretax Profit Margin
35.09%24.50%35.09%38.81%35.03%
Net Profit Margin
28.95%19.96%28.95%32.93%30.09%
Continuous Operations Profit Margin
29.80%20.96%29.80%34.10%30.16%
Net Income Per EBT
82.50%81.45%82.50%84.86%85.92%
EBT Per EBIT
86.99%93.79%86.99%103.53%111.81%
Return on Assets (ROA)
8.92%6.01%8.92%7.70%5.83%
Return on Equity (ROE)
12.61%8.43%12.61%10.50%8.21%
Return on Capital Employed (ROCE)
15.30%9.09%15.30%10.78%7.19%
Return on Invested Capital (ROIC)
12.54%7.66%12.54%8.92%5.99%
Return on Tangible Assets
9.31%6.23%9.31%8.09%5.95%
Earnings Yield
2.00%3.14%2.00%1.02%0.47%
Efficiency Ratios
Receivables Turnover
2.96 2.73 2.96 3.14 2.37
Payables Turnover
10.76 12.25 10.76 8.84 4.77
Inventory Turnover
3.75 5.78 3.75 3.24 2.84
Fixed Asset Turnover
0.59 0.57 0.59 0.52 0.44
Asset Turnover
0.31 0.30 0.31 0.23 0.19
Working Capital Turnover Ratio
1.50 1.50 1.50 0.98 0.68
Cash Conversion Cycle
186.81 167.23 186.81 187.59 206.11
Days of Sales Outstanding
123.31 133.88 123.31 116.10 154.17
Days of Inventory Outstanding
97.43 63.15 97.43 112.78 128.51
Days of Payables Outstanding
33.93 29.80 33.93 41.29 76.57
Operating Cycle
220.75 197.03 220.75 228.88 282.68
Cash Flow Ratios
Operating Cash Flow Per Share
1.33 1.12 1.33 0.78 0.45
Free Cash Flow Per Share
-0.08 0.11 -0.08 -0.70 -0.98
CapEx Per Share
1.41 1.02 1.41 1.48 1.43
Free Cash Flow to Operating Cash Flow
-0.06 0.09 -0.06 -0.90 -2.20
Dividend Paid and CapEx Coverage Ratio
0.94 1.10 0.94 0.53 0.31
Capital Expenditure Coverage Ratio
0.94 1.10 0.94 0.53 0.31
Operating Cash Flow Coverage Ratio
1.25 1.02 1.25 0.80 0.56
Operating Cash Flow to Sales Ratio
0.36 0.27 0.36 0.33 0.34
Free Cash Flow Yield
-0.15%0.40%-0.15%-0.93%-1.15%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
49.89 31.85 49.89 97.89 213.87
Price-to-Sales (P/S) Ratio
14.44 6.36 14.44 32.23 64.36
Price-to-Book (P/B) Ratio
6.29 2.68 6.29 10.28 17.56
Price-to-Free Cash Flow (P/FCF) Ratio
-674.95 247.65 -674.95 -107.28 -87.17
Price-to-Operating Cash Flow Ratio
39.79 23.20 39.79 96.67 192.00
Price-to-Earnings Growth (PEG) Ratio
1.62 -1.41 1.62 1.11 3.61
Price-to-Fair Value
6.29 2.68 6.29 10.28 17.56
Enterprise Value Multiple
35.12 18.75 35.12 72.44 154.63
Enterprise Value
218.55B 103.16B 218.55B 326.98B 357.44B
EV to EBITDA
35.12 18.75 35.12 72.44 154.63
EV to Sales
14.31 6.06 14.31 31.78 63.69
EV to Free Cash Flow
-668.91 235.97 -668.91 -105.75 -86.26
EV to Operating Cash Flow
39.44 22.10 39.44 95.29 190.00
Tangible Book Value Per Share
8.18 10.08 8.18 6.95 4.83
Shareholders’ Equity Per Share
8.40 9.69 8.40 7.33 4.89
Tax and Other Ratios
Effective Tax Rate
0.15 0.14 0.15 0.12 0.14
Revenue Per Share
3.66 4.09 3.66 2.34 1.33
Net Income Per Share
1.06 0.82 1.06 0.77 0.40
Tax Burden
0.83 0.81 0.83 0.85 0.86
Interest Burden
0.99 0.96 0.99 0.99 0.98
Research & Development to Revenue
0.04 0.05 0.04 0.05 0.05
SG&A to Revenue
0.08 0.09 0.08 0.09 0.09
Stock-Based Compensation to Revenue
0.08 0.07 0.08 0.06 0.05
Income Quality
1.03 1.37 1.03 0.86 0.96
Currency in CNY
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis